Eli Lilly vs Novo Nordisk: a Stock Duel
Duel with the 2 GLP-1 and diabetes market leaders
In the pharmaceutical industry, two names have gained significant traction in recent years: Eli Lilly and Novo Nordisk. Both companies are experiencing rapid growth, but the question remains, which one is the better investment?
Based on current results, Novo Nordisk holds a slight edge, thanks to its more favorable valuation and stronger balance sheet. However, Eli Lilly is growing faster, and recent months have seen an upward revision in its expected growth. Additionally, Eli Lilly has a more promising pipeline.
The recent pressure on Novo Nordisk’s stock stems from several factors:
Slowing expected growth (from 22% annually to 20% in the coming months)
Intensifying competition (though most competitors won't be ready for several years)
Stronger results from Eli Lilly’s GLP-1 drug
Regulatory pressures aiming to lower selling prices
A deceleration in growth expectations for the near term
Ultimately, Novo Nordisk may appeal to investors seeking a more reasonable valuation, while Eli Lilly offers a compelling option for those looking for fast growth and momentum. Both stocks show promise, but they also come with high price tags.
For a deeper exploration, check out my article on Novo Nordisk here.
If you like stock duels, you can find here the previous ones:
Here for Dassault Systemes vs PTC
Here for Idexx vs Zoetis
Here for H&M vs Inditex
Here for LVMH vs Hermes
Here for Estée Lauder vs L’Oreal
Here for Nike vs Lululemon
Here for Booking vs Airbnb
Here for Visa vs Mastercard
Here for S&P Global vs Moody’s
Here for Cadence vs Synopsys
Here for Coca-Cola vs Pepsico
Here for Fortinet vs Palo Alto Networks